COLL News and Press, Collegium Pharmaceutical Inc. From 08/06/20

Collegium Pharmaceutical, Inc. (COLL) Q2 2020 Earnings Conference Call August 05, 2020, 16:30 ET Company Participants Alex Dasalla - Head, IR Joseph Ciaffoni - President, CEO & Director Paul Brannelly - EVP & CFO Scott Dreyer - EVP & Chief Commercial Officer Conf...

– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 – – Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020 – – Xtampza ® ER Net Revenue Increased 29% over the Prior Year Pe...

STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and ...

Collegium Pharmaceuticals ( COLL ) has been a stock which intrigued me for quite a while, although I lack conviction on the thesis and a cautious bullish thesis has not played out exactly as planned yet. In February of this year, when COVID-19 was not yet in the spotlights, I concluded ...

STOUGHTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journal’s 2020 Best ...

As if the broad market selloff wasn't enough, Collegium Pharmaceutical ( COLL -3.7% ) is under additional pressure from a report from short seller The Friendly Bear (TFB). Key points: More news on: Collegium Pharmaceutical, Inc., Healthcare stocks news, Stocks on the move, Notable Call...

A coalition of 51 attorneys general in the U.S. has filed an antitrust complaint  in federal court against 26 companies making generic dermatology drugs and 10 executives at these firms claiming wide-spread price-fixing, marketing allocating and bid-rigging related to over 80 different...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

For investors with spare cash on hand, market sell-offs such as this one can provide plenty of opportunities. Stocks with sky-high valuations may have finally fallen to a price where it is reasonable to buy, and stocks that were cheap beforehand may have declined further into a valuation level...

Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...